SGYP Dividend History & Description — Synergy Pharmaceuticals Inc
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Co. is engaged in the discovery, research and development activities around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Co. discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform. Co.'s commercial product, plecanatide, under trademark name TRULANCE is for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. When considering the Synergy Pharmaceuticals Inc stock dividend history, we have taken known splits into account, such that the SGYP dividend history is presented on a split-adjusted ("apples to apples") basis. Synergy Pharmaceuticals Inc dividend history is presented both in graphical/chart form, and as a SGYP dividend history data table along the right-hand column.
SGYP — Key Stats (updated Monday, March 11, 10:20 AM)
The SGYP dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable SGYP historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the SGYP dividend history record. Also see the SGYP stock dividend history data table along the right-hand column below.